Information on the target
Zuellig Pharma, a prominent healthcare solutions provider in Asia, has successfully acquired all rights, title, and interest in Cialis® (Tadalafil), a leading product in men's health, from Eli Lilly and Company (“Lilly”) in Singapore. This acquisition enables Zuellig Pharma to own the trademarks, marketing authorizations, and licenses, as well as the manufacturing know-how for Cialis®, a treatment specifically designed for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). With this expansion, Zuellig Pharma will now manage the brand across 12 markets in Asia, enhancing its presence in Singapore.
The acquisition of Cialis® is a strategic move that will significantly improve accessibility to this essential medication for a large population of men in Asia suffering from ED and BPH. Furthermore, Zuellig Pharma is committed to promoting and distributing the brand in these markets, thereby reinforcing its position as an integrated healthcare solutions company focused on enhancing health outcomes across the region.
Industry overview in the target’s specific country
The Proprietary & Advanced Pharmaceuticals industry in Singapore is characterized by a robust regulatory framework and a strong emphasis on innovation. Singapore has positioned itself as a leading hub for pharmaceutical research and development in Asia, supported by government initiatives aimed at fostering a conducive environment for biopharmaceutical companies. The country’s strategic location, coupled with its advanced infrastructure and skilled workforce, has attracted numerous multinational pharmaceutical firms to establish their regional headquarters and R&D facilities in Singapore.
In recent years, the Singaporean government has implemented various policies to enhance the competitiveness of the pharmaceutical sector. These include tax incentives for R&D activities, grants for innovation projects, and initiatives to streamline regulatory processes. As a result, Singapore has seen a surge in the development of proprietary pharmaceuticals, particularly in areas such as oncology, diabetes, and men’s health, where there is a growing demand for advanced treatment options.
The market for proprietary pharmaceuticals in Singapore is also driven by an increasing prevalence of lifestyle-related diseases and an aging population. As healthcare needs evolve, there is a rising demand for innovative therapies that address specific health concerns, such as erectile dysfunction and benign prostatic hyperplasia. This trend presents significant opportunities for companies like Zuellig Pharma, which are focused on expanding their portfolios with essential healthcare products that cater to these needs.
Moreover, the COVID-19 pandemic has accelerated the adoption of digital health solutions and telemedicine, further transforming the landscape of the pharmaceutical industry in Singapore. Companies are increasingly leveraging technology to enhance patient engagement and streamline…